人表皮生长因子受体2靶向特异性T细胞治疗胃癌的前沿进展  

Advances and prospects of HER-2-specific CAR-T cell in the treatment of gastric cancer

作　　者：杨彩霞 尚轶[1] Yang Caixia;Shang Yi(No.1 Ward of the Department of General Surgery,the Second Hospital of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第二医院普外一病区,730000

出　　处：《中华普通外科学文献（电子版）》2020年第2期150-153,共4页Chinese Archives of General Surgery(Electronic Edition)

摘　　要：目前传统的治疗手段在进一步改善胃癌患者生存率方面无明显优势。随着分子生物学和基因编辑技术的快速发展,一种新型抗肿瘤治疗模式——人表皮生长因子受体2(HER-2)靶向的嵌合抗原受体修饰T细胞(CAR-T)的免疫治疗,展现出了巨大的潜力和治疗前景。CAR-T细胞免疫疗法在治疗实体瘤研究方面取得了长足的进步,但由于胃癌的高度异质性和复杂的肿瘤微环境导致了肿瘤的免疫逃逸,胃癌治疗仍面临诸多挑战。本文就HER-2靶向的CAR-T细胞免疫治疗胃癌的研究进展进行综述,期望其未来成为胃癌安全性高且确切有效的治疗手段。Traditional therapy has limited efficacy on gastric cancer,and with the rapid development of molecular biology and genetic engineering technology,human epidermal growth factor receptor 2(HER-2)-specific chimeric antigen receptor T cell(CAR-T),a new model of adoptive immune cell therapy,has shown tremendous potential and promising prospect.It has a significant effect on hematological malignancies and has made remarkable progress in solid tumor research.However,due to the highly heterogeneous and complex tumor microenvironment,the treatment of HER-2-specific CAR-T cell for gastric cancer is still challenging.In this review,we summarized the development,research progress,challenges and strategies of HER-2-specific CAR-T cells in the treatment of solid gastric cancer,so as to find a safe and effective treatment for solid tumors in the future.

关 键 词：胃肿瘤 受体 抗原 T细胞 受体 表皮生长因子 免疫疗法 过继 

分 类 号：R735.2[医药卫生—肿瘤]